Allogene Therapeutics
Presence
Allogene Therapeutics is one of the...
Allogene Therapeutics is a company listed under the stock ticker ALLO (US).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Allogene Therapeutics
- David Chang, President and Chief Executive Officer
- Deborah Messemer, Director
- Arie Belldegrun, Executive Chairman of the Board
Popular executive movements at Allogene Therapeutics
- Geoffrey Parker has joined the company as Chief Financial Officer (posted on October 17 2023).
- Earl Douglas has joined the company as General Counsel (posted on August 15 2023).
Create your alert
to follow the executive moves at Allogene Therapeutics.
Biotechnology
Allogene Therapeutics has 2,279 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on April 18 2024).
Popular contacts in Biotechnology
News
Press releases by Allogene Therapeutics
- Press Releases | Allogene Therapeutics
- Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences | Allogene Therapeutics
- Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 | Allogene Therapeutics
- Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors | Allogene Therapeutics
- Press Releases | Allogene Therapeutics
- Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma | Allogene Therapeutics
- Press Releases | Allogene Therapeutics
- Press Releases | Allogene Therapeutics
- Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting | Allogene Therapeutics
- Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal | Allogene Therapeutics
- View more press releases Close
Social media about Allogene Therapeutics
- Allogene Therapeutics on Wikipedia, Google News & Yahoo Finance
- Allogene Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including David Chang 
Call Allogene Therapeutics at +1 714...
